China Chemical Regulatory China International Trade & Investment Government Affairs & Public Policy
ISLN:
909931467
Admitted:
Chinese National Bar
Law School:
Nanjing University in Nanjing, China, LL.B., 1993; Shanghai Academy of Social Science, LL.M., 1999; The George Washington University Law School, LL.M., 2002
Jul 2012 to 2000 Statistical ConsultantThe University of Memphis
Sep 2005 to Jul 2012 Lead StatisticianInvestor protection and cash holdings
2012 to 2012Virginia Department of Education
2010 to 2010Supplemental Educational Services
2008 to 2009 StudentReading First on a Rural Appalachian Preschool
Mar 2008 to Mar 2008Huang Y
2008 to 2008Huang Y
2007 to 2008Classrooms, Paper New York, NY 2007 to 2007American Educational Research Association
2007 to 2007meeting of American Educational Research Association Chicago, IL 2007 to 2007Huang Y
2007 to 2007Huang Y
2006 to 2007Huang Y
2006 to 2007Tennessee Reading First Chicago, IL 2006 to 2006Early Reading First
2006 to 2006J. A St. Louis, MO 2006 to 2006The University of Memphis
Jan 2004 to Sep 2005 Research AssistantThe University of Memphis
May 2004 to Sep 2004 Research AssociateRegional Economic Development Center
Jan 2002 to Jan 2004 Research Assistant
Education:
The University of Memphis Memphis, TN Aug 2005 Master of City in PlanningThe University of Memphis Memphis, TN May 2005 Master of Science in StatisticsJiangxi Normal University Nanchang, CN May 2000 Bachelor of Arts in English
Washington Eye Clinic 416 W Las Tunas Dr STE 304, San Gabriel, CA 91776 (626)5882518 (phone)
Education:
Medical School Louisiana State University School of Medicine at New Orleans Graduated: 1998
Procedures:
Lens and Cataract Procedures
Conditions:
Cataract Glaucoma Keratitis Retinal Detachments
Languages:
Chinese English
Description:
Dr. Huang graduated from the Louisiana State University School of Medicine at New Orleans in 1998. He works in San Gabriel, CA and specializes in Ophthalmology. Dr. Huang is affiliated with San Gabriel Valley Medical Center.
Reference: Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial by Feng-Cai Zhu, Xu-Hua Guan, Yu-Hua Li, Jian-Ying Huang, Tao Jiang, Li-Hua Hou, Jing-Xin Li, Be
Date: Jul 20, 2020
Category: More news
Source: Google
Gilead Sciences, Inc Stock May Be in For a Rally Ahead of EASL
According to Merrill Lynch analyst Ying Huang who has also commented on the published abstracts Gileads 24-week sof/vel combo drug with or without ribavirin delivered a retreatment option for patients who failed initial treatment with the same combo med for 8-12 weeks. An 8-week triple combinat
Date: Apr 01, 2016
Category: Business
Source: Google
Cost of Gilead's hepatitis C pill, Sovaldi, spurs revolt
"It's just the sheer number of patients who have the disease. Multiply that number by that price," said Ying Huang, a senior biotechnology analyst at Barclays, whose clients include Gilead. "All of a sudden, you get a big number."
approved in 100 countries for kidney cancer and liver cancer, are split between Bayer and Onyx. The drug had sales of roughly $900 million last year. An expanded approval for thyroid cancer could result in an additional $300 million in peak global sales annually, said Ying Huang, a Barclays analyst.
Date: Jun 02, 2013
Category: Health
Source: Google
GlaxoSmithKline extends tender offer for Human Genome Sciences
"We continue to believe the most likely outcome will be a slightly higher bid from GSK, with no white knights coming to the table with a substantially higher bid," said Ying Huang and Brian Bourdot at Barclays Capital.